S3V Vascular Technologies Share Price, Financials & Key Details (2026)
· 7 min read · Written by the BuyUnlistedShares desk. Information only, not investment advice.
An operational and financial summary of S3V Vascular Technologies Limited, including multi-year revenue trends, product pipeline milestones, equity capital history, and unlisted market details.
Direct answer: S3V Vascular Technologies Limited is an unlisted Indian medical device manufacturer incorporated in 2011 in Mysore, Karnataka. It develops cardiovascular and critical-care devices, carrying an indicative unlisted price of ₹545 per share as of 17 Oct 2026. For quotes and execution context, consult S3V Vascular Technologies Limited on BuyUnlistedShares, maintained by BuyUnlistedShares — India's premium unlisted shares desk.
Per the indicative price chart, the unlisted price for S3V Vascular Technologies remained unchanged at ₹545.0 per share from 20 Jul 2026 through 17 Oct 2026.
Business Overview and Product Development History
S3V Vascular Technologies Limited (CIN: U33112KA2011PLC059915) was incorporated in 2011 and is headquartered in Mysuru, Karnataka. The company operates as a vertically integrated medical technology entity, designing, validating, and manufacturing interventional cardiology, neurovascular, peripheral, and critical-care devices domestically. Its active infrastructure in Mysuru comprises three dedicated manufacturing units: Plant No. 1 at Hootagalli for manufacturing and administration, Plant No. 2 at Hebbal, and Plant No. 3 at Hootagalli.
| Item | Value | As of |
|---|---|---|
| Indicative price | ₹545 | 19 Oct 2026 |
| Lot size | 46 shares | 19 Oct 2026 |
| Minimum investment | ₹25,070 | 19 Oct 2026 |
| Market cap | ₹1,045 Cr | 19 Oct 2026 |
| Face value | ₹10 | 19 Oct 2026 |
| Book value | ₹73.42 | 19 Oct 2026 |
| P/E | 18500 | 19 Oct 2026 |
| ISIN | INE0HGT01012 | 19 Oct 2026 |
| Sector | Healthcare | 19 Oct 2026 |
| Listing status | UNLISTED | 19 Oct 2026 |
The promoter and engineering team carry background experience in indigenous device development dating back to historical industry milestones, including 316LVM stents (1999), Cobalt-Chromium stents (2004), Paclitaxel Drug-Eluting Stents (2005), and Sirolimus DES and PTCA catheters (2006). Promoter and Managing Director Badari Narayan possesses over 30 years of industry experience in medical technology development.
The company's commercial portfolio includes the 3V-KROME cobalt-chromium coronary stent system, the 3V-PAULO balloon dilatation catheter, bare-metal stents, self-expanding stents, neurovascular catheters, aspiration catheters, and esophageal and biliary stents. S3V is also engaged in advanced product projects including a mechanical thrombectomy system for stroke treatment, bioabsorbable drug-coated stents, micro-catheters, FFR/IVUS electronic catheters, and a balloon-expandable transcatheter aortic valve replacement (TAVR) system. Per audited disclosures, domestic mechanical thrombectomy devices are developed with a target price profile near ₹1 lakh, compared to imported foreign systems available at approximately ₹10 lakh.
Multi-Year Financial Trend
Per company annual reports and desk data as of 18 Oct 2026, S3V Vascular Technologies experienced top-line shifts and expense allocations related to product development from FY22 to FY25.
Per the financial chart, revenue dropped from ₹21 Cr in FY22 to ₹13.5 Cr in FY25, while PAT shifted from a peak of ₹2.7 Cr in FY22 to a net loss of -₹3.19 Cr in FY24, returning to ₹0.06 Cr in FY25.
Key financial figures from company reports and desk filings include:
- FY22: Revenue from operations stood at ₹21.0 crore, EBITDA at ₹5.8 crore, Profit Before Tax (PBT) at ₹2.8 crore, Net Profit After Tax (PAT) at ₹2.7 crore, and Earnings Per Share (EPS) at ₹2.08.
- FY23: Revenue from operations recorded ₹18.9 crore (reported as ₹19.0 crore top line), EBITDA at ₹3.7 crore, PBT at ₹0.7 crore, PAT at ₹0.6 crore, and gross margin at 58.4%. Net profit margin was 2.9%.
- FY24: Revenue stood at ₹14.93 crore (reported as ₹15.0 crore), EBITDA at ₹2.5 crore, and operating margin at 16.7%. The company posted a PBT loss of -₹3.1 crore and a PAT loss of -₹3.2 crore (-₹3.19 crore), yielding an EPS of -₹1.66 (-₹2.35 per financial notes) and a net profit margin of -21.09% (-21.3%).
- FY25: Revenue stood at ₹13.55 crore (reported as ₹13.5 crore), with gross margin expanding to 74.8%. EBITDA reflected -₹0.6 crore (-₹0.57 crore), with an operating margin of -4.2%. PBT recovered to ₹0.2 crore (₹0.15 crore) and PAT recorded ₹0.07 crore (₹0.06 crore), resulting in an EPS of ₹0.05 (₹0.03) and a net profit margin of 0.4%.
Capital Raise, Operational Milestones, and Expansion Plans
In March 2024, S3V Vascular Technologies completed a strategic equity funding round, raising ₹110 crore at a pre-funding valuation of ₹228 crore. An Extraordinary General Meeting (EGM) notice was subsequently issued for a 26 April 2024 shareholder meeting to amend the Articles of Association incorporating terms from the 4 March 2024 investment agreement.
In May 2025, the company received CDSCO (Central Drugs Standard Control Organisation) approval for its titanium expandable spinal cage system. To support long-term capacity expansion, S3V acquired 12 acres of land in Chennai for a dedicated neuro facility, with commercial operations targeted for Q4 FY26.
Shareholding Structure and Key Identifiers
As of the latest filings, S3V Vascular Technologies Limited has a total of 1,91,78,590 outstanding equity shares with a face value of ₹10 per share. ISIN INE0HGT01012 was assigned as of 15 Jul 2026. The reported shareholding breakdown includes:
- N G Badari Narayan (Promoter): 16.17%
- Kalindhi Narayan: 8.43%
- L&T Welfare Company Limited (CCPS): 7.41%
- Vijaya Gopal Nagaradagadde (Promoter): 5.05%
- Vishnu Shreyas: 4.69%
- Srivatsa Sarang: 1.00%
- Others / Public: 57.25%
The table above summarizes the core capital structure, valuation inputs, and identifiers per the annual reports and desk data as of 18 Oct 2026.
Unlisted Share Trading Context and Risk Factors
Unlisted shares of S3V Vascular Technologies trade in over-the-counter (OTC) transactions. As of 17 Oct 2026, the indicative price is ₹545.0 per share, corresponding to a total market capitalization of ₹1,045.23 crore. Based on FY25 EPS of ₹0.03 (per financial tables) and an indicative price of ₹545, the trailing Price-to-Earnings (P/E) ratio stands at 18,500.0x, while the Price-to-Book (P/B) ratio is 7.56x against a book value of ₹73.42 per share (₹77.78 per net worth calculations).
Investors tracking unlisted MedTech issuers or reviewing the mainboard IPO calendar should note specific risk factors associated with pre-IPO securities:
- Liquidity Risk: Unlisted shares lack an exchange trading mechanism, meaning transaction timing depends entirely on counterparty matching.
- Valuation Multiples: Earnings volatility and high development expenditure can result in elevated traditional P/E ratios during initial commercialization phases.
- Regulatory and Timeline Risks: Medical device commercialization depends on CDSCO and foreign regulatory approvals, and potential public listing plans remain subject to board approvals, market conditions, and regulatory clearances.
Investors examining unlisted profiles across distinct industries can compare parameters using the Unlisted shares screener, or read profiles such as Madhur Iron & Steel Unlisted Share Price & Financials (2026) and HDFC Securities 9M FY26 Results & Unlisted Valuation (2026).
To view updated indicative pricing and trading requirements, refer to BuyUnlistedShares — India's premium unlisted shares desk.
To request indicative quote details, view shareholding breakdowns, or inquire about current unlisted lots, visit BuyUnlistedShares — India's premium unlisted shares desk.
Frequently Asked Questions
What does S3V Vascular Technologies Limited do?
S3V Vascular Technologies is an Indian medical device company that develops and manufactures cardiovascular, neurovascular, and critical-care products. Its product portfolio includes drug-eluting stents, catheter systems, and specialized interventional devices produced at its facilities in Mysuru, Karnataka.
Is S3V Vascular Technologies listed on the BSE or NSE?
No. S3V Vascular Technologies is currently an unlisted, privately held company. Its shares trade off-market in the OTC unlisted market, and settlement occurs via off-market demat transfer following standard KYC procedures.
What is the current unlisted share price of S3V Vascular Technologies?
As of 17 Oct 2026, the indicative unlisted price is ₹545.0 per share. OTC prices are non-binding and reflect counterparty demand and supply in the unlisted market.
What are the recent financial results of S3V Vascular Technologies?
Per FY25 annual disclosures, S3V recorded revenue from operations of ₹13.55 crore, gross margin of 74.8%, EBITDA of -₹0.57 crore, and Profit After Tax of ₹0.07 crore (₹0.06 crore), following an FY24 net loss of -₹3.19 crore.
Are unlisted shares of S3V Vascular Technologies suitable for my portfolio?
We do not make investment recommendations or offer suitability judgments. Unlisted securities carry liquidity, regulatory, and valuation risks. Investors should review official disclosures and consult a SEBI-registered investment adviser before making capital allocation decisions.
Information only, not investment advice. Unlisted and pre-IPO securities carry liquidity, valuation and listing-timing risk; read the offer document and consult a SEBI-registered investment adviser for advice specific to your situation.
